The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1317
Corrections: Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis and Golimumab (Simponi) for Inflammatory Arthritis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Corrections:

Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis (Med Lett Drugs Ther 2009; 51:49) The first word of the title should have been Biennial, not Biannual.

Golimumab (Simponi) for Inflammatory Arthritis (Med Lett Drugs Ther 2009; 51:55)In Table 1 on page 55, the price for certolizumab (Cimzia) should have been $1,341.68 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Corrections: Biannual IV Zoledronic Acid (Reclast) for Prevention of Osteoporosis and Golimumab (Simponi) for Inflammatory Arthritis
Article code: 1317d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian